Medivir 2021 Annual Report published
Stockholm, Sweden - Medivir AB (Nasdaq Stockholm: MVIR) today announces that the Annual Report for 2021 now is available at the company’s website: www.medivir.com. 2021 started off with the licensing of birinapant to IGM Biosciences, which in November initiated a clinical study in solid tumors with its own DR5 agonist antibody and birinapant. A successful financing that included participation from specialist investors was also carried out at the beginning of the year. Medivir's cutting-edge project fostroxacitabine bralpamide showed positive study results and entered a new clinical phase